U.S. Markets closed

Aveo Oncology, Astellas announce new data presented at ESMO 2012

AVEO Oncology and Astellas Pharma announced new data from the Phase 3 TIVO-1 trial demonstrating the safety and tolerability profile of tivozanib versus sorafenib in the first line setting for patients with metastatic renal cell carcinoma. Results presented at the ESMO 2012 Congress in Vienna, Austria show that patients treated with tivozanib experienced fewer Grade 3 and off-target adverse events, stayed on treatment longer, and required fewer dose reductions and interruptions compared with those treated with sorafenib.1 Also presented were the first tivozanib biomarker data in RCC, and the design of the TAURUS patient preference study, in which the first patient has now been enrolled. AVEO recently submitted a New Drug Application to the U.S. Food and Drug Administration seeking approval for tivozanib.